SoftBank Vision Fund 2 led a series C round for the life science robotics developer at a reported valuation of $1.8bn.
Opentrons, a US-based developer of robotic technology for life science testing, picked up $200m yesterday in a series C round led by telecommunications and internet group SoftBank’s Vision Fund 2.
Venture capital firm Khosla Ventures also participated in the round, which valued the company at $1.8bn according to Bloomberg.
Founded in 2013, Opentrons has built an automated pipetting robot designed for life science research in areas such as drug discovery, genomics and proteomics. The devices can also be used for…
